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ABSTRACT 
Purpose 
The purpose of this study was to determine the visual function and quality of life of 
patients 6 months after undergoing pars plana vitrectomy for diabetic retinopathy 
complications at the Groote Schuur Hospital. The study also investigated the 
association between quality of life and the indications for surgery, the type of 
procedure performed, pan-retinal photocoagulation before surgery, the duration of 
complications, age, gender, the presence systemic disease and best-corrected 
visual acuity (BCVA). 
Method 
The study was a prospective, consecutive, non-comparative case series. This 
observational study evaluated the visual functioning and quality of life using the 
SHORT FORM HEALTH SURVEY (SF-36) and National Eye Institute Visual 
Function Questionnaire (NEI VFQ-39). The SF-36 and NEI VFQ-39 questionnaires 
were administered as an interview to all patients undergoing pars plana vitrectomy 
for diabetic retinopathy. Two interviews were conducted, the first one, a day before 
surgery, and the second, six months after surgery. 
The mean SF-36 and NEI VFQ-39 subscale scores were compared before surgery 
and after surgery to see if there was an improvement. Patient demographics, such 
as age, gender, previous pan-retinal photocoagulation (PRP), indications for 
surgery, LogMAR visual acuity and the type of procedures done were also recorded 
to see if they had any impact on visual functioning and the quality of life scores. 
Results 
43 patients were interviewed using the SF-36 and NEI VFQ-39 questionnaires. The 
mean age of the study population was 55 years of age. 73% of the respondents 
reported having had PRP before surgery.  
The Wilcoxon Signed Rank Test was used to compare pre-operative and post-
operative measurements. Significant improvement was found in the post-operative 
values in three of twelve VFQ-39 subscales, namely general vision, near activities, 
and peripheral vision. The SF-36 questionnaire showed significant improvement in 
emotional well-being and significant worsening in fatigue. A statistically significant 
improvement in post-operative visual acuity LogMAR values was found. The mean 
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LogMAR value improvement was from 2.1 to 1.0. No significant differences were 
noted in the NEI VFQ-39 subscale between the group that had prior PRP and the 
group that did not have prior PRP, nor with different waiting times for surgery, 
indications for surgery or the type of surgery performed. There was a significant 
correlation between the LogMAR visual acuity of the operated eye and the vision-
related quality of life score. 
Conclusion 
Significantly, the study showed a marked improvement in visual acuity. 
 Although there was significant improvement in patient’s perception of their general 
vision, near activities and peripheral vision, this study showed that vitrectomy for 
diabetic retinopathy, does not improve the overall vision-related quality of life.  
Patients presented with an advanced stage of retinopathy resulting in severe 
impairment in their quality of life and very low baseline quality of life scores 
associated with decreased visual acuity in both eyes. In this study, vision-related 
quality of life was dependent on both operated and non-operated eye. There was a 
correlation between visual acuity and the NEI VFQ-39 scores in both operated on 
and non-operated on eyes. The study showed that patients undergoing vitrectomy 
for diabetic retinopathy had much lower NEI VFQ-39 scores than patients who did 
not need vitrectomy, as compared to the Okomoto study that compared vitrectomy 
for PDR vs. a control (1). The study showed that patients with poor vision before 
vitrectomy tended to continue to have poor vision after vitrectomy, whereas those 
with good vision pre-operatively tended to continue to have good vision post-
operatively.  
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CHAPTER 1  
INTRODUCTION AND BACKGROUND 
1.1 Research Problem 
The most commonly used conventional measure of visual function, distance acuity, 
does not adequately reflect visual functioning and the ability to perform vision 
dependent tasks (21). 
 Distance acuity is measured on a high contrast letter chart containing letters of 
progressively smaller sizes, which subtend progressively smaller angles at the focal 
point on the retina. These letters serve as a marker for the ability of the eye to 
resolve objects. Distance acuity is easily and quickly determined, hence its 
popularity in the clinical setting. However, traditional measures of visual acuity (VA) 
may be insufficient to provide necessary information regarding aspects of visual 
function that may be vital for patients’ daily routine activities. 
Ophthalmologists increasingly emphasise the importance of outcomes, such as 
physical function, social function and overall health, in addition to standard clinical 
outcome, when evaluating treatment for eye disease (22, 9). However, measures of 
visual functioning and quality of life have rarely been incorporated into clinical 
studies of vitrectomy for diabetic retinopathy.  
1.2 Purpose of Study  
The purpose of this study was to determine both the visual functioning and the 
quality of life of patients with diabetic retinopathy undergoing pars plana vitrectomy 
(PPV) at Groote Schuur Hospital. 
1.3 Research Questions 
• Is there an improvement in quality of life in patients after vitrectomy for 
diabetic retinopathy? 
• Do the indications for vitrectomy affect the patient’s post-operative quality of 
life? 
• Do gender or age or both have an effect on post-operative quality of life for 
patients with diabetic retinopathy? 
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• Is there a difference in quality of life for different surgical procedures done? 
• Is there a correlation between quality of life and other diabetic complications, 
e.g., cardiovascular accident, cardiac disease and renal disease? 
• Does waiting time for surgery affect patient quality of life after PPV? 
• Does having pan-retinal photocoagulation (PRP) before the operation have 
an effect on quality of life after PPV? 
1.4 Research Hypothesis 
Vitrectomy resulted in significant changes in post-operative visual acuity (BCVA) in 
the operated eye. 
Vitrectomy did not result in any changes in visual acuity (BCVA) of the non-operated 
eye. 
Vitrectomy resulted in significant changes in post-operative vision and general 
health related quality of life for patients as measured by the NEI VFQ-39 and SF-36.  
1.5 Variables 
The research aimed to find out what the predictor variables for visual outcome and 
quality of life were after pars plana vitrectomy for diabetic eye disease. The following 
outcome variables were evaluated: 
• Age 
• Gender 
• Visual outcome 
• Pan retinal photocoagulation treatment before operation 
• Indications for pars plana vitrectomy 
• Surgical procedure performed in theatre 
• Waiting time for surgery 
• Presence of systemic disease such as renal disease, cardiac disease and 
cerebral vascular accident. 
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1.6 Background 
Diabetes mellitus results in considerable morbidity and mortality affecting about 180 
million people worldwide (13). The disease is divided into, Type I DM (previously 
insulin dependent DM) and Type II DM (previously non-insulin dependent DM). The 
total number of people with diabetes is expected to rise to an estimated 300 million 
cases by the year 2025 (34). 
People with diabetes are at risk for developing a number of irreversible 
complications that can be largely divided into micro-vascular and macro-vascular 
complications. The macro-vascular complications include cerebrovascular disease, 
coronary heart disease and peripheral vascular disease. The micro-vascular 
complications include diabetic retinopathy, diabetic neuropathy and diabetic 
nephropathy. 
Diabetic retinopathy is the most common complication in Type I DM and nearly all 
patients will have some degree of retinopathy 15–20 years after diagnosis. Similarly, 
more than 60% of Type II diabetic patients will show evidence of diabetic retinopathy 
after having had the disease for 20 years (46). 
Approximately 4.1 million American adults, 40 years and older, have diabetic 
retinopathy; one in every 12 individuals with DM in this age group has advanced, 
vision-threatening retinopathy (26). 
Diabetic retinopathy is a progressive and inevitable complication of diabetic mellitus, 
in which retinal capillaries are damaged. The damaged capillaries become leaky and 
occluded, which is the stage termed 'non-proliferative diabetic retinopathy'. The 
retina attempts to compensate for damaged capillaries by Neovascularisation, a 
stage termed 'proliferative diabetic retinopathy'. However, the proliferating vessels 
are weak and prone to damage. Once the vessels rupture and haemorrhage, 
fibrosis may occur, which in turn damages other retinal cells so that peripheral vision 
may be impaired. 
Central vision is affected when the damage occurs at or near the macula. Ultimately, 
blindness results from macular non-perfusion, retinal detachment or vitreous 
haemorrhage (33).  
Diabetic retinopathy is one of the most common causes of blindness in developed 
countries affecting mostly patients in their working years (age 20–65). People with 
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diabetic mellitus are 25 times more likely than the general population to become 
blind (26). In 2002, diabetic retinopathy accounted for about 5% of world blindness (25). 
By incorporating the self-reporting of visual functioning and health-related quality of 
life into clinical studies, it may be possible to demonstrate the positive impact of pars 
plana vitrectomy in patients with advanced diabetic retinopathy, which may not be 
demonstrated by clinical measurements such as visual acuity. Diminished visual 
acuity has been associated with decreased performance in activities of daily living, 
poorer cognitive abilities, an increased risk of falls and ultimately poorer health 
related quality of life (19, 24). Loss of vision carries significant economic and 
psychological costs for both individuals and society (23).  
1.7 Proliferative Diabetic Retinopathy 
Proliferative diabetic retinopathy (PDR) represents the most severe manifestation of 
diabetes in the eye. It is the result of the loss of normal retinal perfusion and the 
subsequent development of neovascular proliferative tissue in the fundus. The 
development of this neovascular tissue reflects an alteration in the balance between 
angiogenesis inhibitors and stimulators in the retina and the vitreous. Multiple local 
chemical mediators (cytokines) are believed to be at work. It is associated with 
bleeding, resulting in vitreous haemorrhage. The new vessels may undergo fibrosis 
and contraction; this and other fibrous proliferation may result in epiretinal 
membrane formation, vitreoretinal traction bands, retinal tears, and tractional or 
rhegmatogenous retinal detachments.  
1.8 Clinical Signs 
Neovascularisation of the disc (NVD) is neovascularisation that develops on the 
surface of the optic nerve or within one disc diameter of the optic nerve.  
The term Neovascularisation Elsewhere (NVE) refers to retinal neovascularisation 
anywhere in the fundus that is not at the disc. Neovascularisation elsewhere in 
retina tends to occur in the posterior pole or midperiphery. Neovascularisation of the 
Iris (NVI) is an ominous sign because it can cause neovascular glaucoma (NVG), 
leading to a blind and painful eye. 
Vitreous haemorrhage from NVD or NVE may occur and produce preretinal or 
vitreous haemorrhage. Vitreous haemorrhage is more likely when NVD and NVE are 
more extensive. Haemorrhages are usually spontaneous and produce a sudden 
development of floaters. Preretinal haemorrhage reflects sequestration of blood 
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between the inner retinal surface and an intact posterior hyaloid face. Therefore, this 
will generally occur in younger patients. This may produce a dense, well-
circumscribed scotoma. Preretinal haemorrhage may break into the vitreous and 
produce more diffuse floaters characteristic of vitreous haemorrhage. Vitreous 
haemorrhage is often recurrent and can lead to profound visual loss. 
1.9 Diabetic Macular Edema (DME) 
DME is retinal thickening within one disc diameter (DD) of the centre of the macula. 
It is defined as the collection of intraretinal fluid in the macular area of the retina, 
with or without lipid exudates or cystoid changes. When DME causes retinal 
thickening or hard exudates with adjacent retinal thickening that threatens the centre 
of the macula, it is considered "clinically significant”; whether present in NPDR or 
PDR, DME results from micro aneurysms or other focal or diffuse vascular leakage 
within or near the macula. Visual acuity is generally compromised when DME affects 
the fovea. DME can occur at any stage of diabetic retinopathy; approximately 15% 
of patients with diabetic retinopathy have DME. The incidence of DME increases as 
diabetic retinopathy progresses from non-proliferative diabetic retinopathy to 
proliferative diabetic retinopathy.  
1.10 Pars Plana Vitrectomy 
Vitrectomy is the treatment of choice in proliferative diabetic retinopathy with vitreo-
retinal traction, vitreous haemorrhage and maculopathy (38). It can frequently restore 
useful vision in diabetic patients and reduce the risk of irreversible visual loss due to 
retinal detachments. 
At least 51% of diabetics receiving optimal medical treatment will still develop 
progressive retinopathy requiring laser treatment and pars plana vitrectomy (46).  
The outcome for vitreous surgery for proliferative diabetic retinopathy has improved 
over the past decade because both instrumentation and surgical techniques have 
been refined. Despite the success of pars plana vitrectomy in managing the severe 
complication of diabetic retinopathy, operative and post-operative complications still 
occur, leading to anatomical failure and blindness. Such complications include 
recurrence of retinal detachments, development of neovascular glaucoma (NVG), 
hypotony with subsequent ptysis bulbi, and lens opacities (44). 
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Since pars plana vitrectomy can improve anatomic features and functional visual 
acuity (VA), even for patients with advanced diabetic retinopathy, it has become the 
mainstay of therapy for complications of proliferative diabetic retinopathy (PDR). 
1.11 Summary of Chapters 
Chapter One indicates the importance of the study. It also highlights the purpose 
and objectives of the study and links the study to the current situation in diabetic 
retinopathy. It introduces the indications of vitrectomy in diabetic retinopathy and the 
significance of vision-related quality of life study. 
Chapter Two links the objectives and purpose of the study to the published 
literature. It gives an overview of what has already been done in this field of 
research. 
Chapter Three gives the detailed methodology used to undertake the study. 
Chapter Four records the results of the research and contextualises the 
applicability of the findings as a basis for the discussion and recommendations in 
Chapter Five. 
Chapter Five  interprets the results recorded in Chapter Four and highlights further 
research opportunities. 
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CHAPTER 2  
LITERATURE REVIEW 
2.1 Prevalence of Diabetic Retinopathy 
The prevalence of diabetic retinopathy in the United States was found to be 33.2% 
and macular oedema 9.0% (26). Retinopathy and macular oedema were found to be 
significantly higher in Blacks, 36.7% and 11.1%, compared to whites, 24.8% and 
2.7%(26). In Maseru, Lesotho, diabetic retinopathy was found in 47.8% of 
153 consecutive diabetic clinic patients, background retinopathy was present in 
78% of patients with retinopathy and 22% had proliferative changes (65).  
2.2 Impact of Diabetic Retinopathy on Economy 
Visual disorders result in a substantial economic burden on the economy. The cost 
of diabetic retinopathy in the United States is estimated to exceed US$ 500 million, 
per year (33).  
2.3 Impact of Diabetic Retinopathy on Patients 
Visual loss can affect every aspect of a patient’s life. In a Lions Club survey, visual 
loss was reported to be one of the most feared complications of diabetes, more than 
amputation or heart attack (36). Visual loss is associated with a higher than normal 
risk of depression and it can hinder daily activities associated with independence (37). 
Everyday visual loss has a significant impact on patients’ lives, affecting the way 
they experience and interact with the world (37). 
2.4 Quality of Life Questionnaires 
A number of questionnaires have been developed to measure health-related quality 
of life. The best known and most widely validated is the medical outcome study,   
36-item short form (SF-36) questionnaire (35).  
The SF-36 has been used in numerous outcomes studies of general medical 
diseases (e.g., diabetes and hypertension) and ophthalmic conditions such as 
uveitis, cataract, glaucoma, and age-related macular degeneration diabetic 
retinopathy, corneal transplantation, keratoconus, optic neuritis and ocular 
melanoma (1,3,4,7,8,927,28,16,18). The SF-36 measures health status across eight 
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dimensions, namely physical functioning, role limitation caused by physical 
disability, bodily pain, general health, vitality, social functioning, role limitation 
caused by emotional disability and mental health (29). 
The National Eye Institute sponsored the development of a vision-related quality of 
life (VR-QOL) questionnaire (NEI VFQ-39) that could be used for individuals with 
diverse eye diseases (2, 30). The 39-item NEI VFQ-39 contains 12 subscales and is 
both reliable and valid  (2). A composite score can also be computed from each of the 
vision-related scales (i.e., the average of all 11 subscales excluding the general 
health subscale).  
The NEI VFQ-39 is a reliable and valid 39-item version of the 51-item National Eye 
Institute Visual Function Questionnaire (NEI VFQ). It is especially useful in settings 
such as clinical trials, where short interview duration is a critical consideration (2). 
2.5 Previous Quality of Life Studies 
The National Eye Institute Visual Function Questionnaire (NEI VFQ) was developed 
to test the psychometric impact of diseases that cause vision loss. Patients with 
age-related eye disease were found to have a decreased quality of life as measured 
by the Short Form Health Survey-36 (SF-36) and National Eye Institute Visual 
Function Questionnaire (NEI VFQ). In this regard, every ophthalmologist is a quality 
of life expert. Most of us devote our days not to adding years to life, but rather 
adding life to years. 
Previous studies reported that vision-related quality of life (VR-QOL) significantly 
improved following vitrectomy. In patients with epiretinal membrane (ERM), 
vitrectomy improved two of the 12 National Eye Institute Visual Function 
questionnaire subscales (NEI VFQ-39), (general vision and distance activities) (6). In 
patients with ERM, vitrectomy improved subjective perception of visual function as 
indicated by higher composite scores in the NEI VFQ-39 (6). Central retinal vein 
occlusion was associated with a decreased vision-related quality of life (9). 
A number of studies have assessed the quality of life in patients with vitreoretinal 
diseases, such as age-related macula degeneration. It was found that patients with 
vitroretinal disease had reduced visual-related quality of life that was often better 
correlated with self-reported visual impairment than with visual acuity (1, 6, 9). 
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2.6 Management Diabetic Retinopathy 
The primary goal of current therapies for diabetic retinopathy is to reduce the risk of 
vision loss. In general, prompt treatment is advised for patients with high-risk 
proliferative diabetic retinopathy and clinically significant diabetic macular oedema.  
Current treatments for proliferative diabetic retinopathy and diabetic macular 
oedema are pan-retinal (scatter) laser photocoagulation and focal laser 
photocoagulation, respectively (49). Laser photocoagulation is the standard, most 
widely used technique for treating diabetic retinopathy. A vitrectomy is a surgery 
commonly used for patients who has developed vitreous haemorrhage. While these 
procedures are generally effective in stabilising or reducing vision loss, they do have 
limitations. They do not cure underlying diabetes, so patients are always at risk for 
additional retinopathy. Surgery does not reverse micro vascular damage associated 
with diabetic retinopathy. In addition, laser therapy, as an invasive procedure, 
damages the retina. 
2.6.1 Laser treatment for diabetic retinopathy 
An early treatment diabetic retinopathy study (ETDRS) showed that immediate focal 
photocoagulation reduced the likelihood of patient losing ≥  15 ETDRS letters by 
50% for up to 3 years (46). 
Full scatter photocoagulation reduces the rate of developing high-risk proliferative 
diabetic retinopathy by approximately 50% (46). Timely application of laser 
photocoagulation is the mainstay of treatment to reduce visual loss and to avoid the 
need for vitrectomy in patients with more advanced forms of diabetic retinopathy. 
Even in eyes with severe retinopathy, only pan-retinal photocoagulation (PRP) may 
improve the subsequent surgical outcome (46). 
2.6.2 Medical management of diabetic retinopathy 
Systemic glycaemic control 
The diabetic control complication trial (DCCT) showed that intensive control of 
glucose at a level of HBA1C of 7.2% substantially reduced the risk of the onset and 
progression of diabetic retinopathy (48). 
The United Kingdom Prospective Diabetes Study (UKPDS) showed a 25% risk 
reduction in micro vascular complications if glucose was controlled at an HBA1C 
of 7.0%.  
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The UKPDS also showed that controlling blood pressure (BP) 144/82 reduced the 
risk of micro vascular disease by 37% and the risk of retinal photocoagulation by 
35%. Therefore, the control of blood pressure should have a high priority in the 
treatment of Type II DM (45). 
2.7 New Pharmacotherapy 
Protein kinase C (PKC) inhibitors 
PKC inhibitors are being developed to reduce micro vascular complications in 
patients with diabetes. One of these is ruboxistaurin, which is a specific inhibitor of 
PKC and has been found to block vascular complications of diabetes, including 
abnormalities in retinal blood flow; neovascularisation and VEGF mediated effects 
on permeability (49). 
Antivascular endothelial growth factors (anti VEGF) 
Macugen (pegaptanib), Lucentis (ranibizumab) and Avastin (bavisizumab) 
These have been demonstrated to inhibit vascular endothelial growth factors 
(VEGF) (118). A preliminary analysis suggests that these agents are effective against 
DME and proliferative diabetic retinopathy (59). 
Corticosteroid 
Triamcinilone reduced macular oedema and improved visual acuity for 6 months (58). 
Posardex 
Biodegradable, implantable, extended release that delivers dexamethazone directly 
to posterior segment for a period of 35 days. This is under investigation (49). 
2.7.1 Vitrectomy surgery for diabetic retinopathy 
Vitrectomy is an intraocular surgery used for patients with proliferative diabetic 
retinopathy who develop vitreous haemorrhaging that does not resolve 
spontaneously and/or develops a tractional retinal detachment (38). With a vitrectomy, 
blood and vitreous is removed from the eye and replaced with intraocular 
tamponading agent, e.g., silicone oil, SF6 gas or C3F8. Vitreous attached to the 
retina is also removed if it is causing traction that could lead to retinal detachment or 
tears. The complications of surgery include recurring vitreous haemorrhaging and 
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retinal detachment, which can result in severe vision loss. There are reports in the 
literature suggesting that vitrectomy surgery may be helpful in eyes with refractory 
macular oedema (57). Some eyes with tangential vitro macular traction may not be 
responsive to laser photocoagulation. 
Machemer et al. performed the earliest successful vitrectomy, in 1970, in an eye 
with diabetic vitreous haemorrhage (38). 
2.8 Indications for Surgery 
The major indications for vitrectomy in a patient with diabetic retinopathy are (38): 
Media opacities 
• Non-clearing vitreous haemorrhage 
• Subhyaloid, sub macular haemorrhage 
• Anterior segment neovascularisation with posterior segment opacity 
Vitreoretinal tractions 
• Progressive fibro vascular proliferation 
• Tractional retinal detachment involving macula 
• Combined tractional and rhegmatogenous retinal detachment 
Maculopathy 
Macula oedema associated with a taut, persistently attached posterior hyaloid (54). 
Other  
• Vitreous Hemorrhage/ghost cell glaucoma 
• Retinal detachment – traction or rhegmatogenous 
• Anterior hyaloid fibro vascular proliferation 
• Epiretinal membrane 
Currently, surgical intervention for non-clearing diabetic vitreous haemorrhage is 
usually considered at an earlier time. Since patients with Type II DM have a higher 
rate of spontaneous resolution of haemorrhage and slower progression of fibro 
vascular proliferation, the usual approach for patients with Type II DM is to defer 
surgical intervention longer than for patients with Type I diabetes. Vitrectomy is often 
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considered within a few weeks for Type I diabetic patients, especially if severe 
vitreous haemorrhage has shown no sign of spontaneous clearing (38). 
A second indication for pars plana vitrectomy includes preretinal tractional defect. 
Tractional retinal detachment is the single most common indication for vitrectomy. 
Because peripheral and mid peripheral tractional retinal detachment progress to 
involve the macula in only 15% of cases per year, vitrectomy is only recommended 
for localised detachment that involves or clearly threatens the macula (46). This class 
now constitutes the majority of patients undergoing vitrectomy for complications due 
to diabetic retinopathy. 
The spectrum of this includes macular heterotopia, progressive fibro vascular 
proliferation (FVP) without retinal detachment, and tractional retinal detachment and 
rhegmatogenous retinal detachment with a break caused by progressive traction. 
Frequently, FVP with traction coexists with vitreous haemorrhage. Progressive fibro 
vascular proliferation occurs despite appropriate panretinal photocoagulation, 
especially in Type I diabetics. 
2.9 Surgical Objectives and Techniques 
The objective of pars plana vitrectomy for advanced diabetic retinopathy is to 
remove axial opacities, relieve tangential and anteroposterior tractions, treat all 
retinal breaks and deliver laser treatment. 
Media opacities 
The removal of axial opacities involves the vitreous cutter and in some cases the 
Lensectomy instrument. Vitrectomy instruments now offer a wide choice of cutting 
rates and suction pressure for removal of entire posterior cortical vitreous. 
Vitreoretinaltraction 
The release of traction involves removal of anteroposterior and tangential traction. 
Several techniques have been developed to achieve this goal. 
Segmentation technique 
This is sequential dissection of anterior-to-posterior vitreous traction, scissors 
dissection of bridging epiretinal membranes and, finally, removal of residual islands 
of surface traction (epiretinal membrane).  
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Delaminating technique 
The anterior to posterior traction is removed. Horizontal scissors and multifunction 
instruments (such as lighted picks or lighted forceps) are used to remove the 
preretinal tissue at the retinal plane in one or more large pieces. 
Enbloc technique 
The surface traction is removed with scissors as a large, confluent piece, with the 
anteroposterior traction used for counter traction. 
2.10 Visual Outcome after Vitrectomy 
Macular ischemia has been found to be the most significant predictor of a poor 
visual outcome following pars plana vitrectomy (PPV) for diabetic retinopathy (44).  
Other risk factors for poor visual outcome include pre-operative and post-operative 
iris neovascularisation (NVI) and postoperative vitreous haemorrhage (44). 
Only a small proportion of patients who require PPV present with vitreous 
haemorrhaging as the sole cause of visual loss. The majority of patients present 
with varying degrees of pre-operative vitreoretinal traction, retinal detachment, 
capillary nonperfusion and macular oedema, which may influence the final visual 
acuity outcome in patients with diabetic retinopathy (44). 
Mason et al., found that 16% of patients had worsening but functional vision, defined 
as worse but still less than 20/40: 4% had worsened, but had ambulatory vision, 
defined as count fingers (CF) or hand motion (HM); and 7% had poor visual 
outcome light perception (LP) or no light perception (NLP) (44). 
2.11 Lens Extraction at the Time of Vitrectomy 
Before endolaser photocoagulation was available, aphakic eyes often developed 
post-operative rubeosis iridis. Improved techniques for lens removal have improved 
outcomes (52). Combining vitrectomy with phacoemulsification, an intraocular lens 
implant is often necessary as the phakic diabetic patient needing vitrectomy will 
often develop lens changes after surgery (51). Combined surgery offers the 
advantages of a single intervention compared with multiple trips to the operating 
room, shorter recovery time and good post-operative visualisation if additional laser 
is needed and earlier ability to surgically treat the unoperated eye (52). 
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2.12 Summary 
There have been many advances in the treatment of diabetes and diabetic 
retinopathy and its complications over the past 25 years. There is a better 
understanding of the importance of optimising glycaemic control and hypertension 
control, both of which directly reduce the micro vascular complications of diabetes. 
The major advances in treating macular oedema with a focal laser have been a 
result of clinical trials over the past 25 years. The surgical management of 
proliferative diabetic retinopathy, vitreous haemorrhage and tractional retinal 
detachment has been greatly facilitated by the development of the endolaser probe, 
indirect laser and improved vitrectomy machines and instrumentation. 
Pharmacotherapy is making an impact on the treatment of diabetic retinopathy and 
many treatments are currently under investigation. The future holds promise with 
improved pharmacotherapy that may decrease the progression of diabetic 
retinopathy and diabetic macular oedema and help with the treatment of the many 
complications that can occur due to proliferative diabetic retinopathy, including 
vitreous haemorrhage and tractional retinal detachment. 
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CHAPTER 3  
RESEARCH METHODOLOGY 
3.1 Introduction 
Quantitative research was employed in this study as a mechanism to understand the 
perception of quality of life of respondents both before and after vitrectomy. 
3.2  Population and Sample 
The study was conducted at the Groote Schuur Hospital Ophthalmology 
Department. All patients that underwent pars plana vitrectomy for diabetic 
retinopathy complications were included in the study. 
Forty-three patients were recruited for the study. There were no refusals. Patients 
that were undergoing a repeated vitrectomy for any reason were excluded from the 
study. 
The study was conducted from June 2007 to December 2008.  
The following pre-operative information was obtained from each patient: age, 
gender, duration of diabetic mellitus, other systemic complications of diabetes, the 
indication for surgery, the waiting time for surgery, the type of procedures performed 
and whether pre-treatment with panretinal photocoagulation was performed or not. 
The Snellen best-corrected visual acuity (BCVA) was obtained preoperatively and 
6 months postoperatively. 
3.3 Surgical Procedures 
Six different vitreo-retinal surgeons, one full time and five part time, performed all 
the surgeries. All surgeries were performed under general anaesthesia. The 
crystalline lens was removed and an intraocular lens implanted when required, this 
was followed by a 20 gauge, 3-port pars plana vitrectomy, posterior hyaloid 
separation and removal of the posterior vitreous membrane. Membrane dissection 
and segmentation was performed when necessary. Peripheral vitrectomy and 
panretinal endophotocoagulation were routinely performed, as well as air fluid 
exchange and SF6 gas or silicone oil fill. 
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3.4 Instruments and Data Collection  
In this study, we used the Short Form Health Survey (SF-36) and National Eye 
Institute Visual Function Questionnaires (NEI VFQ-39) to measure visual functioning 
and quality of life in patients with diabetic retinopathy complications who underwent 
pars plana vitrectomy at Groote Schuur Hospital.  
A trained interviewer administered questionnaires to 43 patients, both one day 
before surgery and 6 months following surgery. The study was conducted between 
June 2007 and December 2008. 
The NEI VFQ comprised 39 items. Patients were expected to assess their level of 
difficulty with particular visual symptoms or day-to-day activities; each item was 
assigned to one of the following twelve subscales. 
General health 
General vision 
Ocular pain 
Near activities 
Distance activities 
Vision specific social functioning 
Vision specific role difficulties 
Vision specific mental health 
Vision specific dependency 
Driving 
Colour vision 
Peripheral vision 
The subscales were scored on a 0–100-point scale, where 100 indicated the highest 
possible function or the least impairment. The NEI VFQ-39 composite score was 
calculated as the un-weighted average response to all items, excluding the question 
regarding general health. 
SF-36 comprised 36 items for which patients were expected to assess their level of 
difficulty with a particular aspect of day-to-day activities; each item was assigned to 
one of the following eight subscales: 
Physical functioning 
Role limitation due to physical health 
Role limitation due to emotional problems 
Energy/fatigue 
Emotional well-being 
Social functioning 
Pain 
General health 
All the questions were scored on a scale from 0–100, with 100 representing the 
highest level of functioning possible. The scores from the questions that addressed 
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each specific area of functional health status were then averaged for a final score 
within each of the eight dimensions measured. 
3.5 Validity and Reliability 
Reliability refers to the extent to which the same or similar results can be obtained 
using the research methodology under different circumstances, at different times 
and using different respondents or interviewers.  
Validity is the extent to which a research design measures what it purports to 
measure (42). 
The NEI VFQ-39 and SF-36 questionnaires used in this study have been validated, 
as they have been used on people with common eye conditions (31) and they have 
appeared in publications (1, 6, 7, 9, 39). The original questionnaires were used in this 
study without alterations. 
3.6 Research Design and Strategy 
This was a quantitative, prospective, non-comparative case series. The eligibility of 
participants to answer the questionnaires was assessed using nine structured 
questions (see Appendix 8). Patients had to have a score of 80% in order to be 
included; this was to exclude those patients who were unreliable from answering 
questionnaires. All participants were eligible for the study. The mini-mental status 
exam was not used because it was thought to take too long. 
3.7 Ethics 
Ethics refers to the moral principles or values that generally govern the conduct of 
an individual or group. In research, researchers have a responsibility to the sponsor 
and the respondents. The respondents have the right to privacy, safety, know the 
true purpose of the research, the research results and decide which questions to 
answer (43).  
The University of Cape Town Ethics Committee and UCT’s Department of Surgery 
Research Unit both approved the study. The ethical protocol was maintained at all 
stages of the study and each participant gave consent before conducting the 
interview.  
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Permission to use questionnaires 
RAND granted permission to use "RAND 36-Item Short Form Health Survey". The 
36-Item Health Survey was developed at RAND as part of the medical outcomes 
study. No written permission was needed for use of this Health Survey (35). The 
National Eye Institute allowed the use of the NEI VFQ-39 as long as there was an 
acknowledgement of the developers of this questionnaire. 
3.8 Data Analysis 
All data collected was captured into an Excel programme and coded. The SF-36 and 
the NEI VFQ-39 summary and subscale scores from one day before the operation, 
were computed according to published algorithms (29, 33) and compared with the 
mean scores, 6 months after the operation.  
The mean scores and standard deviations were calculated for each NEI VFQ-39 
and SF-36 subscale result as well as the composite score. A One Sample 
Kolmogorov-Smirnov test was performed to compare each subscale score and 
composite score before and after surgery. The Wilcoxon signed-ranks test was used 
for variables that were present both pre-operatively and post-operatively. The 
relationship of the questionnaire scores with visual acuity, gender, age, indications 
for surgery, pre-operative panretinal photocoagulation, systemic disease, waiting 
time for surgery and type of procedure performed were examined by the Spearman 
rank correlation test. To correlate the visual acuity with the questionnaire score, the 
Snellen visual acuity was converted to its LogMAR: equivalent approximation. The 
VA of counting fingers was converted to 20/2000; hand motion was converted to 
20/4000 and light perception was converted to 20/8000 (9). 
All tests of association were considered statistically significant if p<0.05.  
Due to the sample size being only 43 in total, the statistical methods used were non-
parametric in nature. In the non-parametric statistics range, the data is ranked and 
these ranks are compared and a z-statistic is computed to indicate the significance 
of the difference between the rankings. Mean scores are not used as the basis of 
analysis in non-parametric analysis. 
A One-Sample Kolmogorov-Smirnov Test was used initially to determine if the 
sample was normally distributed. The Mann-Whitney U test was used for cases 
where groups were compared such as gender groups. The variables, in such cases, 
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were categorical in nature and this warranted the use of this test. The Spearman 
Rho test was used to establish differences between continuous variables. 
The procedure followed was as given below: 
1 Initially, the data file was split into data for the left eye (cases where the 
procedure was performed on the left eye) and data for the right eye (cases 
where the procedure was performed on the right eye). This was done to 
ensure that any changes to the procedure would be clearly observable and 
would not be contaminated by the other eye. 
2 For further analysis, the data file was combined into one data file and the 
same analysis was performed on the data for both eyes. This was done to 
obtain statistics regarding changes in overall functioning. 
3 The raw data was used in most cases except in the case of the NEI VFQ-39 
and SF-36. In these cases, the raw data was used as the basis for compiling 
scale scores, utilising the appropriate scoring formula for each instrument. A 
separate spreadsheet was used to compile subscale scores. The 
transformed scores were imported back into the main data set. 
4 The SPSS (Statistical Package for the Personal computer) version 16.0 was 
used for analysing the data. 
The following hypotheses were tested: 
• Vitrectomy resulted in significant changes in post-operative visual acuity 
(BCVA) in the operated eye. 
• Vitrectomy did not result in any changes in visual acuity (BCVA) of the non-
operated eye. 
• Vitrectomy resulted in significant changes in post-operative vision and 
general health related quality of life of patients as measured by the  
NEI VFQ-39 and SF-36.  
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CHAPTER 4  
FINDINGS 
4.1 Introduction 
This chapter is descriptive rather than interpretive; it records the results of the 
survey and contextualises the findings together with the purpose and rationale 
behind the construction of the survey instrument.  
4.2 Demographic 
4.2.1 Gender 
Table 1 indicates the gender distribution of the sample. 
Table 1: Gender distribution of the sample 
  
Frequency % Valid % 
Cumulative 
% 
 Male 22 51.2 51.2 51.2 
Female 21 48.8 48.8 100.0 
Total 43 100.0 100.0  
 
51% of all respondents were male. The rationale for this was to evaluate whether 
gender affected the quality of life after vitrectomy. 
4.2.2 Age 
The youngest respondent was 25 years old and the oldest 77. On average, the 
respondents were 55 years old, with the standard deviation at 10.83. The age 
distribution of the sample is provided in the Figure 1. 
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Figure 1: Age distribution of the sample 
 
The age distribution across gender groups is displayed in the Figure 2. 
 
Figure 2: Age distribution across gender groups 
The rationale was to evaluate whether age affects health-related quality of life. 
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4.3 Previous PRP 
Table 2 below illustrates, as a percentage, the number of patients who had 
panretinal photocoagulation before vitrectomy: 
Table 2: Percentage of patients who had PRP before vitrectomy 
 
  Frequency % Valid % Cumulative % 
 Yes 28 65.1 73.7 73.7 
No 10 23.3 26.3 100.0 
Total 38 88.4 100.0  
Missing  5 11.6   
Total 43 100.0   
 
73.7% of the respondents had PRP before vitrectomy. The rationale for including 
PRP was to assess whether panretinal photocoagulation before vitrectomy improved 
visual-related quality of life.  
4.4 Waiting Time for Surgery 
Figure 3 indicates the duration patients waited for their surgery from the time of 
diagnosis of indication requiring surgery to the time they actually had surgery. The 
rationale for including this was to evaluate whether delaying vitrectomy had an 
impact on the overall results of vitrectomy. Waiting	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Figure 3: Waiting time for surgery 
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• 44% had surgery within four months of the diagnosis indicating a need for 
vitrectomy.  
• 56% of patients waited for more than four months for their vitrectomy.  
• 7% waited twelve months for their vitrectomy. 
4.5 Type of Surgery Performed 
• 62% of patients had pars plana vitrectomy and epiretinal membrane peeling. 
• 14% had PPV and retinal detachment repair.  
• 24% had PPV and lens extraction. 
4.6 Indications for Vitrectomy 
The rationale for evaluating indications for vitrectomy was to find out whether vision-
related quality of life differed for different indications. 
Table 3: Indications for vitrectomy 
 Frequency % 
Vitreous hemorrhage 20 46.5 
Tractional retinal detachment 17 39.5 
Combined tractional and 
rhegmatogenous retinal detachment 
5 11.6 
Macula oedema 1 2.3 
Total 43 100.0 
 
4.7 Visual Outcome after Vitrectomy 
There was significant improvement in LogMAR BCVA from mean 2.0 pre-operative 
to 1.0 post-operative (p=0.0001). Pre-operative LOGMAR ranged from 0.00 to 3, 
with 82% ranging from 0.8 to 3 and 9% 0.3 or better, and post-operative LogMAR 
ranged from 0.00 to NPL. 60% had LogMAR ranging from 0.8 to 3; 4% had NPL and 
10% LogMAR 0.3 or better. 
There was no significant difference in LogMAR values for non-operated eye pre- 
and post-vitrectomy (mean 1.4 pre- and 1.2 post-vitrectomy). 
The following graphs indicate LogMAR visual acuity for both operated and non-
operated eyes. 
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Figure 4(a) 
 
Figure 4(b) 
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Figure 4(c) 
 
Figure 4(d) 
 
Figure 4(a)–(d): LogMAR visual acuity for both operated and non-operated eyes 
 
Scatter plots are visual representations of the comparison between two variables. It 
is basically a cross tabulation between the two variables. 
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Figure 5 below shows: 
• a scatter plot for the pre- and post operative- visual acuity  
• a scatter plot for the pre- and post vitrectomy visual acuity 
 
Figure 5(a) 
 
 
Figure 5(b) 
Figure 5(a)–(b): Visual acuity pre- and post-vitrectomy 
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The rationale for this was to find out if there was significant improvement in visual 
acuity after vitrectomy and using the non-operated eye as a control. 
4.8 Scatter Plot for the Visual Acuity Trend Pre and Post
 Operative 
The following graph indicates a scatter plot for pre- and post-LogMAR values for the 
operative and non-operative group, as well as a plot for the difference between pre 
and post values. 
 
Figure 6: Scatter plot for pre- and post-LogMAR values for the operative and non-
operative group 
 
• The Y axis represents pre-operative values and the X axis represents post-
operative values. 
• Fit-lines were added to the plot to show trends in the data. These fit lines 
show the trend of the relationship between pre- and post-vitrectomy. 
• The green line (representing the relationship between pre- and post non-
operative LogMAR values) indicates that LogMAR values pre- and post are 
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more or less the same. The green line is almost diagonal (gradient = 0.815) 
in the graph, so for LogMAR 0 on Y, the corresponding X value would be 0 
as well. 
• The blue fit line indicates the relationship between pre- and post-operative 
LogMAR values. This line is less diagonal than the green line (gradient = 
0.26). This shows an improvement due to the operation. For LogMAR 2.00 in 
the Y, there is corresponding improvement in LogMAR to 1.00 in X axis, 
which shows that this is the trend in the relationship. 
• The red fit line indicates the relationship between calculated pre- and post- 
difference in LogMAR value. This line is even less diagonal (gradient not 
shown) than either of the other two and this shows the improvement in the 
difference values. In general, it shows an improvement in LogMAR values 
from pre-operative to post-operative.  
4.9 Results for Visual Related Quality of Life Scores 
 Table 4: NEI VFQ-39 questionnaire subscale scores 
 
NEI VFQ-39  
Questionnaire 
subscales 
Mean 
Pre 
operative 
Std. Deviation 
Pre operative 
Mean 
Post 
operative 
Std. 
Deviation 
Post 
Operative 
P value as 
compared 
with pre-
operative 
value 
General health  45.8 19.3 37.8 24.0 0.093 
General vision  43.0 19.4 53.6 31.9 0.032 
Ocular pain  69.9 26.7 47.8 37.0 0.005 
Near activities  27.2 28.8 37.6 36.9 0.012 
Distance activities  30.4 28.9 36.8 31.9 0.173 
Vision specific social 
functioning  37.6 35.7 24.9 22.8 0.042 
Vision specific mental 
health  27.3 27.9 33.8 39.7 0.523 
Vision specific  
role difficulties  
29.8 29.9 39.2 36.2 0.257 
Vision specific 
dependency  33.8 38.5 38.3 44.9 0.618 
Driving  8.6 22.5 2.4 9.3 0.038 
Colour vision  48.8 38.9 36.0 44.4 0.051 
Peripheral vision  29.0 33.6 51.2 44.6 0.002 
Composite score  35.0 23.1 32.2 27.9 0.346 
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The NEI VFQ-39 subscale scores that were markedly reduced and worse were for 
driving, near activities, peripheral vision, vision specific mental health, vision specific 
role difficulties, distance activities, vision specific dependency and the composite 
score. 
There was statistically significant difference six months post vitrectomy in seven of 
12 VFQ subscales, with improvement in three of the 12 subscales, namely general 
vision (p=0.032), near activities (p=0.012), peripheral vision (p=0.002).  
There was worsening in colour vision (p=0.051), vision specific social functioning 
(p=0.042) and driving (P=0.038) and ocular pain .There was no statistically 
significant difference in the composite score 6 months (p=0.005) post vitrectomy 
4.10 Gender Groups 
There were no significant differences in vision-related quality of life between gender 
groups. This is in itself indicated that both male and female perceptions of their 
vision-related daily activities were equally affected. 
 
4.11 Previous PRP and the VFQ-39 Subscales 
4.11.1 Post-operative 
No significant differences were observed in the subscale scores between those who 
had undergone previous PRP and those who had not. 
4.11.2 Pre-operative 
A significant difference was observed for pre-operative driving; those who had 
undergone PRP ranked higher on this dimension. 
4.11.3 Cardiac Disease 
Patients with cardiac disease had lower post-operative NEI VFQ-39 subscale scores 
than those without cardiac disease. Patients with cardiac disease showed significant 
worsening of six of 12 subscales, namely vision specific mental health (p=0.020), 
colour vision (p=0.049), peripheral vision (p=0.056), general vision (p=0.42), ocular 
pain (p=0.027), distance activities (p=0.030) and the composite score (p=0.042). 
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 There was significant worsening of the composite score (p=0.042). Patients with 
cardiac disease had significant worsening of vision-related quality of life 6 months 
after vitrectomy for diabetic retinopathy. 
4.11.4 Renal Disease 
There was no statistically significant difference in vision-related quality of life 
6 months after vitrectomy, if patient had renal disease. 43% of patients with renal 
disease died within 6 months of vitrectomy. 
4.11.5 CVA Post Operative 
A significant improvement was noted in one subscale of the NEI VFQ-39 subscale, 
namely, colour vision (p=0.051). 
4.11.6 Type of Surgery Performed  
There was no significant difference in quality of life in different type of surgery 
performed. 
4.14 Indications for Surgery  
There was no significant difference in the quality of life in different indications for 
surgery.  
 
4.15 Results for the Health-Related Quality of Life Scores 
Table 5 below indicates the mean scores for the SF-36 questionnaire both before 
and after vitrectomy.  
The health-related quality of life scores showed severe impairment in role limitation 
due to emotional problems, role limitation due to physical health and general health. 
There was no statistically significant difference in the health-related quality of life 
(HRQoL) 6 months after vitrectomy for diabetic retinopathy. A significant general 
improvement was noted in role limitation due to emotional problem (p=0.055), 
although patients had less energy after vitrectomy (p=0.032). 
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 Table 5: SF-36 subscale scores pre- and post-operative 
 
Mean 
Pre-op 
Std. 
Deviation 
Pre-op 
Mean 
Post-op 
Std. 
Deviation 
Post-op 
Asymp. Sig. 
(2-tailed) 
Physical functioning 62.3 31.3 62.6 30.2 0.118 
Role limitations due to 
physical health 18.2 21.8 22.1 26.7 0.472 
Role limitations due to 
emotional problems 15.9 19.9 28.9 27.6 0.055* 
Energy/fatigue 62.7 25.1 56.1 27.8 0.032 
Emotional well being  62.8 26.6 65.3 28.0 0.96 
Social functioning 45.5 21.9 46.4 22.4 0.94 
 Pain 73.5 33.1 66.0 39.9 0.414 
General health  35.9 22.3 32.7 23.1 0.262 
    
 
4.16 Correlations between the Visual Acuity and the Visual 
Function Scores 
The Spearman’s RHO test showed significant correlations between the operated 
and non-operated eye LogMAR values and the NEI VFQ-39 subscales and the 
composite score (p=0.04). 
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CHAPTER 5  
DISCUSSION 
5.1 Demographics 
There were equal numbers of male and female patients enrolled in the study, which 
indicated that there was no gender bias with regard to access to the health services. 
A risk factor for diabetic retinopathy is the duration of disease and retinopathy is 
expected to occur 5 to 20 years after diagnosis of diabetes (46).  
The mean age in the study was 55, (range 25–77); this was similar to that of the 
Early Treatment Diabetic Retinopathy Study (ETDRS) study group. Nearly 50% of 
patients in the ETDRS were younger than 50 years (49). Okomoto also found that the 
mean age of patients with proliferative diabetic retinopathy was 55 (1).  
Although the visual function scores may decrease with age, the patient age did not 
correlate well with the patients’ responses in this study.  
5.2 Factors that Could Influence the Outcome of Vitrectomy 
5.2.1 Panretinal photocoagulation (PRP) 
26% of patients did not have PRP prior to vitrectomy. This indicated that patients 
presented late in their disease. One would expect people requiring vitrectomy to 
have had panretinal photocoagulation according to the diabetic retinopathy study 
(DRS) (46). One of the reasons for late presentation may have been that diabetic 
retinopathy screening and referral for laser treatment was inadequate. Currently, 
there is no diabetic retinopathy screening programme in South Africa.  
The lack of a diabetic screening programme results in more patients presenting in 
the advanced stage of their disease. Theoretically, laser treatment reduces 
complications during vitrectomy, such as intra and postoperative vitreous 
haemorrhage, which affects the visual outcome of vitrectomy (44). However, in this 
study, there was no statistical difference in quality of life in patients that had or had 
not had PRP before vitrectomy. 
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5.2.2 Waiting time for surgery 
Due to a shortage of vitreoretinal specialists, significant waiting lists for vitreous 
surgery had developed, and 56% of patients had to wait for more than 5 months for 
vitrectomy. We expected patients who had waited longer for surgery to have less 
improvement in their quality of life and visual outcome; however, in this study, there 
was no statistically significant difference in the outcome with respect to different 
waiting times.  
5.2.3 Type of surgery performed 
Patients with vitreous haemorrhage who did not have traction or macular ischemia 
or oedema have a good prognosis for good visual outcome (38). The majority of 
patients in this study had some form of traction of the macula, which required 
membrane peeling and this had an impact on their visual prognosis. This resulted in 
the poor visual acuity and low quality of life scores before and after vitrectomy. 
There was no statistically significant difference in their quality of life scores when 
comparing the different surgical procedures performed.  
5.2.4 The indications for vitrectomy 
Vitreous haemorrhage and tractional retinal detachment was the commonest 
indication for vitrectomy, as was also found in other studies (38, 44, 52, 53, 54). There was 
no statistical difference in quality of life for the different indications for vitrectomy. 
One would expect patients with vitreous haemorrhage to have better quality of life 
scores after vitrectomy; however, this was not demonstrated in this study. This was 
probably because patients presented late in their disease and the majority had some 
form of traction of the macula. In the Okomoto study, patients with vitreous 
haemorrhage had higher vision-related quality of life subscale scores 3 months after 
vitrectomy (1). 
5.3 No Difference in Quality of Life in Different Factors that May 
Affect the Outcome of Vitrectomy 
A possible explanation for there being no difference in quality of life in different 
factors that may affect the outcome of vitrectomy was that most of patients already 
had ischemic macula at the time of surgery. The perfusion of the macula is the main 
determinant of the post-operative visual outcome (38).  
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Smidy reported that some patients who had vitreous haemorrhage also had some 
elements of traction and macular ischemia (49), which resulted in poor visual 
functioning post vitrectomy. 
5.4 Visual Outcomes 
There was a statistically significant improvement in visual acuity after vitrectomy 
from mean LogMAR of 2.06 to mean 1.04 in the operated eye, whereas there was 
no statistical difference in the pre-operative and post-operative LogMAR values of 
the non-operated eye. The Okamoto study showed an improvement in vision from 
LogMAR 1.4 to LogMAR of 0.46 three months after vitrectomy for proliferative 
diabetic retinopathy. The visual acuity in this study was much lower than in other 
published series. This is largely because our patients presented in an advanced 
stage of retinopathy and patients had severely impaired visual acuity in both eyes.  
Although there was a statistical improvement in visual acuity, this was improvement 
from counting fingers to 6/60.  
Six months after vitrectomy, 56% of patients had visual acuity from 6/60 to hand 
motion and 26% had visual acuity better than 6/12, in the operated eye. Mason 
showed >6/12 in 38% of patients, 6/60 to hand motion in 21%, similar to other 
studies (38, 44, 61, 62, 63). This showed that our patients had a lower visual acuity level as 
compared to other studies; however, the other studies were carried out in developed 
countries with better resources. 
5.5 Vision-Related Quality of Life after Vitrectomy 
In this study, the quality of life after vitrectomy depended on the visual acuity of the 
operated eye, which is contrary to other published studies that showed that quality 
of life after vitrectomy depended on the visual acuity of the non-operated eye. The 
non-operated eye had good vision in their series (1, 5, 6).  
In this series, both eyes were similarly involved; hence, the operated eye had an 
impact on the quality of life. The vision in the non-operated eye was considerably 
impaired (LogMAR 1.2) and the difference between the operated and non-operated 
eyes was small (1.0 vs. 1.2). The visual function score correlated with the visual 
acuity not only in the non-operated eye but also in the operated eye.  
These results are inconsistent with other studies that found that changes in visual 
functioning scores were linearly related to changes in visual acuity of the better-
seeing eye, but were not associated with changes in the worse seeing eye (5, 9, 1).  
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Previous studies reported that quality of life significantly improved following 
vitrectomy for AMD, macular hole, ERM peeling and proliferative diabetic 
retinopathy. (1, 5, 9). However, in this study, patients had better baseline vision-related 
quality of life scores before vitrectomy because it was a unilateral disease. In 
patients with macular hole, four of the 12 subscales (general vision, near activities, 
mental health and role difficulties) improved significantly after vitrectomy. In several 
studies investigating quality of life outcomes following vitrectomy, weak or absent 
correlation between increased quality of life and improvement of visual acuity was 
found. This was because in these studies the non-operated eye had a good vision. 
(10, 64) 
Vitrectomy for ERM significantly improved two of the 12 subscales (general vision 
and distance activities). Vitrectomy for PDR significantly improved eight of the 
12 subscales (general vision, near activities, distance activities, social functioning, 
mental health, role difficulties, driving and peripheral vision) (1). 
In this study, vitrectomy for diabetic retinopathy improved in three of the 
12 subscales of the NEI VFQ-39 (general vision, near activities and peripheral 
vision). Other studies all showed better improvement in visual functioning scores 
than in this study, where there was no significant change in the vision-related quality 
of life 6 months after vitrectomy. These patients had severely impaired vision-related 
quality of life before vitrectomy, with a composite score of 35, because they 
presented with very advanced diabetic retinopathy. The pre operative NEI VFQ-39 
scores were much lower in this study than in Okamoto study and other published 
studies (1, 5, 6, 9, 64). There are limited resources in South Africa's health care facilities 
as compared to developed countries with excellent health facilities, where most of 
the studies have been done; this is a major contributor to the difference in these 
results. 
Although there was no significant improvement in vision-related quality of life 
6 months after vitrectomy, the patients' perception of peripheral vision significantly 
improved. Our findings suggest that, as Snellen acuity does not measure peripheral 
vision, self-reported measures of visual functioning and quality of life (activities of 
daily vision) may augment the clinical findings and it may be useful to compare and 
follow up patients with advanced diabetic retinopathy. 
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5.6 General Health Related Quality of Life 
The SF-36 scores for the vitality domain were significantly reduced post-operatively, 
with patients reporting feeling tired. This may be the result of other systemic 
pathologies, e.g., cardiac disease and renal disease. It is also possible that 
vitreoretinal surgery and the associated postoperative recovery are tiring for the 
elderly and could result in reduced vitality, even 6 months post-operatively. This is of 
importance when counselling patients for such vitreous surgery. 
5.7 Limitations of the Study 
Sample size: The sample size was small and there was no comparison control 
group.  
Short-term follow-up: In the macular hole study, vision-related quality of life was 
better at one-year than at 3-months postoperatively (5Long-term follow-up of patients 
after pars plana vitrectomy for diabetic retinopathy might give different results 
regarding VR-QOL, therefore, future research with longer follow-up and larger 
sample size is needed. 
Advanced diabetic retinopathy: The advanced levels of diabetic retinopathy in this 
sample mean that generalisations from our findings can only be made about 
patients with the same health care service. Also, the study was performed at a 
single tertiary care specialty hospital and therefore may not represent the patients 
who are seen in other tertiary hospital centres. Notwithstanding these limitations, 
this study’s strengths include its prospective design and the use of validated 
instruments. It was done in Africa, in a public sector where 80% of the patients are 
treated, and other studies in similar settings have not been published. 
5.8 Conclusion and Recommendations 
Significantly, the study showed a marked improvement in visual acuity. 
 Although there was significant improvement in patient’s perception of their general 
vision, near activities and peripheral vision, this study showed that vitrectomy for 
diabetic retinopathy, did not improve the overall vision-related quality of life.  
Patients presented with an advanced stage of retinopathy resulting in severe 
impairment in their quality of life and very low baseline quality of life scores 
associated with the decreased visual acuity in both eyes. In this study, vision-related 
quality of life was dependent on both the operated and the non-operated eye. There 
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was correlation between visual acuity and NEI VFQ-39 scores in both operated and 
non-operated eyes. The study showed that patients undergoing vitrectomy for 
diabetic retinopathy had much lower NEI VFQ-39 scores compared to patients who 
did not need vitrectomy, when compared to the Okomoto study, which compared 
vitrectomy for PDR vs. control (1). This study showed that patients with poor vision 
before vitrectomy tended to continue to have poor vision after vitrectomy, whereas 
those with good vision pre-operatively tend to continue to have good vision post-
operatively.  
A better understanding of the positive impact of vision-preserving therapies on 
quality of life and, specifically, on a patient’s capacity for independent living may 
preserve resource allocation for therapies designed to treat diabetic retinopathy.  
There is a need to develop a diabetic screening programme in order to prevent 
patients presenting in such an advanced stage of the disease. Patients must also be 
aware of the need for early detection of diabetic retinopathy by a thorough 
examination through a dilated pupil to assess whether treatment is needed to 
prevent visual loss. Early referral to eye care facilities is necessary. 
There should be a national eye health education programme responsible for 
education about diabetes and the need for diabetic retinopathy screening to patients 
and family members. 
Secondary prevention in diabetic retinopathy needs to be improved with more 
patients getting laser treatment. The government needs to evaluate the need for 
vitreoretinal surgeons and employ such surgeons according to the burden of 
disease, so that patients do not have to wait for more than 5 months for vitrectomy.  
Patients' macular perfusion status should be assessed prior to vitrectomy by means 
of a fluorescein angiogram. Patients should have extensive pre-operative 
counselling on what to expect from the surgery, based on the study results. 
Patients will benefit from the introduction of supportive rehabilitation centres and 
low-vision clinics, where teams of social workers, orientation and mobility instructors 
and rehabilitation teachers can help patients develop coping strategies. 
Although diabetic retinopathy is an inevitable sequel of diabetic mellitus, it can be 
influenced by glycaemic control, timely diagnosis and treatment through vitrectomy. 
Vision-related quality of life questionnaires are useful for assessing the outcome of 
vitrectomy in patients with very advanced diabetic retinopathy. 
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APPENDICES 
Appendix 1: Letter of Consent 
This serves to assure you as a respondent that this interview is solely for research 
purposes.  
Your name will remain anonymous. 
The information you supply will not be used for anything other than for the purpose 
of this research. The results of this study will be made available to every 
respondent. The study intends to enrol 200 participants. 
The study will be conducted by means of two questionnaires before surgery and 4 
months and 6 months after surgery. Each interview will last for 15 minutes. 
Questions will be related to quality of life and visual functioning. Overall duration of 
the study will be 24 months. 
Your participation is voluntary. 
You may choose not to be included in this research. If you choose not to participate 
in this study, it will not, by anyhow, affect the quality of service to be rendered to 
you, either by the person under taking the research or any person rendering service 
to you. If in the middle of the study you choose to withdraw from participating in the 
study, there will be no prejudice to quality of clinical management and care rendered 
to you. 
The information to be given will remain confidential. 
 
Thank you for choosing to participate in this research. 
The aim of this research is to evaluate the quality of life and visual functioning after 
parsplana vitrectomy for patients with diabetic eye disease complications. 
The researcher will contact you on the days of interviews. The follow-up interview 
will be conducted on the day of your follow-up visits to the retinal clinic. Therefore, 
no reimbursement will be made to participants. 
A research report will be submitted to the University of Cape Town (UCT), Western 
Cape, South Africa, in partial fulfilment of the requirement for the Masters degree in 
ophthalmology (MMED). 
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The researcher is Dr BVUMBI AZWIHANGWISI, the Registrar in Ophthalmology 
Department (UCT) GROOTESCHUUR HOSPITAL. Contact details are 021 404 
3525 (phone) and/or 082 3385 538 (mobile). 
The Health Science Research Ethics Committee of the University of Cape Town, 
which reviews research on human subjects, will answer any question about your 
rights and welfare as a research subjects. You may contact Professor MARC 
BLOCKMAN at 021 406 6496 or 021 406 6338. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
  
47 
Appendix 2: Patient Information Sheet 
 
Thank you for choosing to be included in this research. 
The study topic of this research is to evaluate the quality of life and visual 
functioning after parsplana vitrectomy for patients with diabetic eye disease 
complications in Groote Schuur Hospital Western Province. 
The results of the study will help the ophthalmology fraternity in future 
recommendations of treatment. Results will help in assessing the overall impact of 
surgery on patients’ quality of life. 
The study will be conducted by means of two questionnaires, one before surgery 
and the other 4 months and 6 months after surgery. Each interview will last for 15 
minutes. Questions will be related to quality of life and visual functioning. The overall 
duration of the study will be 24 months. 
There are no benefits or disadvantages attached with being included or not being 
included in the study. The study intends to enrol 200 participants. 
The researcher will contact you on the days of interviews. A follow-up interview will 
be conducted on the day of your follow-up visits to the retinal clinic. Therefore, no 
reimbursement will be made to participants. 
The researcher is Dr BVUMBI AZWIHANGWISI, the Registrar in the Ophthalmology 
Department (UCT) GROOTESCHUUR HOSPITAL. Contact details are 021 404 
3525 (phone) and/or 082 3385 538 (mobile). 
The Health Science Research Ethics Committee of the University of Cape Town, 
which reviews research on human subjects, will answer any question about your 
rights and welfare as a research subjects. You may contact Professor MARC 
BLOCKMAN at 021 406 6496 or 021 406 6338. 
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Appendix 3: Demographic Form 
 
Name  
Hospital  Hospital number  
  Title 
(Office Use only) 
 
Date Time Venue Interviewer 
Interviewer’s comment 
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Appendix 4:  SF-36 Questionnaire 
Instructions: These questions ask for your views about your health. This information will 
help keep track of how you feel and how well you are able to do your usual activities. 
Answer every question by marking the answer as indicated. If you are unsure about how to 
answer a question, please give the best answer you can. 
1 In general, would you say your health is: (Please tick one box) 
 Excellent q  
 Very Good q  
 Good q  
 Fair q  
 Poor q  
2 
 
Compared to one year ago, how would you rate your health in general now? 
(Please tick one box) 
 Much better than one year ago  q 
 Somewhat better now than one year ago  q 
 About the same as one year ago  q 
 Somewhat worse now than one year ago q 
 Much worse now than one year ago  q 
3 The following questions are about activities you might do during a typical day.  
Does your health now limit you in these activities? If so, how much? 
(Please circle one number on each line) 
 
 Activities 
Yes, 
limited 
a lot 
Yes, 
limited 
a little 
Not 
limited 
at all 
3(a)  Vigorous activities, such as running, lifting 
heavy objects, participating in strenuous sports 
1 2 3 
3(b) Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling, or playing 
golf 
1 2 3 
3(c)  Lifting or carrying groceries  1 2 3 
3(d)  Climbing several flights of stairs  1 2 3 
3(e) Climbing one flight of stairs 1 2 3 
3(f)  Bending, kneeling, or stooping 1 2 3 
3(g)  Walking more than a mile 1 2 3 
3(h) Walking several blocks 1 2 3 
3(i)  Walking one block  1 2 3 
3(j) Bathing or dressing yourself   1 2 3 
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4 During the past 4 weeks, have you had any of the following problems with your 
work or other regular daily activities as a result of your physical health? 
 (Please circle one number on each line) Yes No 
4(a) Cut down on the amount of time you spent on work or other 
activities  1 2 
4(b)  Accomplished less than you would like  1 2 
4(c)  Were limited in the kind of work or other activities  1 2 
4(d) Had difficulty performing the work or other activities (for 
example, it took extra effort) 
 
1 2 
5 During the past 4 weeks, have you had any of the following problems with your 
work or other regular daily activities as a result of any emotional problems (eg 
feeling depressed or anxious)? 
 (Please circle one number on each line) Yes No 
5(a)  Cut down on the amount of time you spent on work or other 
activities  1 2 
5(b) Accomplished less than you would like  1 2 
5(c) Didn’t do work or other activities as carefully as usual  1 2 
    
6 During the past 4 weeks, to what extent has your physical health or emotional 
problems interfered with your normal social activities with family, friends, 
neighbours, or groups? (Please tick one box) 
 Not at all q  
 Slightly q  
 Moderately q  
 Quite a bit q  
 Extremely q  
 
 
7 How much physical pain have you had during the past 4 weeks? (Please tick 
one box) 
 None q  
 Very mild q  
 Mild q  
 Moderate q  
 Severe q  
 Very severe q  
 
8 During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)? (Please tick one box) 
 Not at all q  
 A little bit q  
 Moderately q  
 Quite a bit q  
 Extremely q  
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9 These questions are about how you feel and how things have been with you 
during the past 4 weeks. Please give the one answer that is closest to the way 
you have been feeling for each item.  
 (Please circle one number on each line) 
All of 
the 
time 
Most 
of the 
time 
A good 
bit of 
the 
time 
Some 
of the 
time 
A 
little 
of the 
time 
None 
of 
the 
time 
9(a) Did you feel full of life?  1 2 3 4 5 6 
9(b) Have you been a very nervous 
person?  
1 2 3 4 5 6 
9(c) Have you felt so down in the 
dumps that nothing could cheer 
you up? 
1 2 3 4 5 6 
9(d) Have you felt calm and peaceful?  1 2 3 4 5 6 
9(e) Did you have a lot of energy? 1 2 3 4 5 6 
9(f) Have you felt downhearted and 
blue? 
1 2 3 4 5 6 
9(g) Did you feel worn out? 1 2 3 4 5 6 
9(h) Have you been a happy person? 1 2 3 4 5 6 
9(i) Did you feel tired?  
 
1 2 3 4 5 6 
10 During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting with 
friends, relatives etc) (Please tick one box) 
 All of the time q  
 Most of the time q  
 Some of the time q  
 A little of the time q  
 None of the time 
 
q  
11 How TRUE or FALSE is each of the following statements for you? 
 (Please circle one number on 
each line)  
Definitely 
true 
Mostly 
true 
Don't 
know 
Mostly 
false 
Definitely 
false 
11(a) I seem to get sick a little easier 
than other people 
1 2 3 4 5 
11(b) I am as healthy as anybody I 
know 
1 2 3 4 5 
11(c) I expect my health to get worse  1 2 3 4 5 
11(d) My health is excellent  1 2 3 4 5 
 
Thank you 
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Appendix 5: Visual Function Questionnaire 
 
Visual Functioning Questionnaire – 39 (NEI VFQ-39) 
(INTERVIEWER ADMINISTERED FORMAT) 
Instructions:  
I’m going to read you some statements about problems that involve your vision or 
feelings that you have about your vision condition. After each question, I will read 
you a list of possible answers. Please choose the response that best describes your 
situation. 
Please answer all the questions as if you were wearing your glasses or contact 
lenses (if any). 
Please take as much time as you need to answer each question. All your answers 
are confidential. In order for this survey to improve our knowledge about vision 
problems and how they affect your quality of life, your answers must be as accurate 
as possible. Remember, if you wear glasses or contact lenses for a particular 
activity, please answer all of the following questions as though you were wearing 
them. 
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VISUAL FUNCTIONING QUESTIONNAIRE – 39 
PART 1 – GENERAL HEALTH AND VISION 
1 In general, would you say your overall health is: (Circle One) 
 Read categories:  
 Excellent 1 
 Very good 2 
 Good 3 
 Fair 4 
 Poor 5 
   
2 At the present time, would you say your eyesight, using both eyes (with glasses or 
contact lenses, if you wear them), is excellent, good, fair, poor, or very poor or are 
you completely blind? (Circle One) 
 Read categories:  
 Excellent 1 
 Good 2 
 Fair 3 
 Poor 4 
 Very poor 5 
 Completely blind 6 
   
3 How much time do you worry about your eyesight? (Circle One) 
 Read categories:  
 None of the time 1 
 A little of the time 2 
 Some of the time 3 
 Most of the time 4 
 All of the time 5 
   
4 How much pain or discomfort have you had in and around your eyes? (for example, 
burning, itching, or aching) Would you say it is: (Circle One) 
 Read categories:  
 None 1 
 Mild 2 
 Moderate 3 
 Severe 4 
 Very severe 5 
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PART 2 – DIFFICULTY WITH ACTIVITIES 
 
The next questions are about how much difficulty, if any, do you have doing certain activities 
whilst wearing your glasses or contact lenses, if you use them for that activity.	  
	  
5 How much difficulty do you have reading ordinary print in newspapers? Would you 
say you have: (Circle One) 
 Read categories as needed:  
 No	  difficulty	  at	  all 1 
 A	  little	  difficulty 2 
 Moderate	  difficulty	    3 
 Extreme	  difficulty 4 
 Stopped doing this because of your eyesight 5 
 Stopped doing this for other reasons or not interested	  in	  doing	  this	   6 
   
6 How much difficulty do you have doing work or hobbies that require you to see well 
up close, such as cooking, sewing, fixing things around the house, or using hand 
tools? Would you say: (Circle One) 
 Read categories as needed:	    
 No	  difficulty	  at	  all 1 
 A	  little	  difficulty 2 
 Moderate	  difficulty	    3 
 Extreme	  difficulty 4 
 Stopped doing this because of your eyesight 5 
 Stopped doing this for other reasons or not interested	  in	  doing	  this	   6 
   
7 Because of your eyesight, how much difficulty do you have finding something on a 
crowded shelf? (Circle One) 
 Read categories as needed:  
 No	  difficulty	  at	  all 1 
 A	  little	  difficulty 2 
 Moderate	  difficulty	    3 
 Extreme	  difficulty 4 
 Stopped doing this because of your eyesight 5 
 Stopped doing this for other reasons or not interested	  in	  doing	  this	   
 
 
 
6 
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8 How much difficulty do you have reading street signs or the names of stores?  
(Circle One) 
 Read categories as needed:  
 No	  difficulty	  at	  all 1 
 A	  little	  difficulty 2 
 Moderate	  difficulty	    3 
 Extreme	  difficulty 4 
 Stopped doing this because of your eyesight 5 
 Stopped doing this for other reasons or not interested	  in	  doing	  this	   6 
   
9 Because of your eyesight, how much difficulty do you have going down steps, stairs, 
or curbs in dim light or at night? (Circle One) 
 Read categories as needed:  
 No	  difficulty	  at	  all 1 
 A	  little	  difficulty 2 
 Moderate	  difficulty	    3 
 Extreme	  difficulty 4 
 Stopped doing this because of your eyesight 5 
 Stopped doing this for other reasons or not interested	  in	  doing	  this	   6 
   
10 Because of your eyesight, how much difficulty do you have noticing objects off to the 
side while you are walking along? (Circle One) 
 Read categories as needed:  
 No	  difficulty	  at	  all 1 
 A	  little	  difficulty 2 
 Moderate	  difficulty	    3 
 Extreme	  difficulty 4 
 Stopped doing this because of your eyesight 5 
 Stopped doing this for other reasons or not interested	  in	  doing	  this	   6 
   
11 Because of your eyesight, how much difficulty do you have seeing how people react 
to things you say? (Circle One) 
 Read categories as needed:  
 No	  difficulty	  at	  all 1 
 A	  little	  difficulty 2 
 Moderate	  difficulty	    3 
 Extreme	  difficulty 4 
 Stopped doing this because of your eyesight 5 
 Stopped doing this for other reasons or not interested	   6 
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in	  doing	  this	   
12 Because of your eyesight, how much difficulty do you have picking out and matching 
your own clothes? (Circle One) 
 Read categories as needed:  
 No	  difficulty	  at	  all 1 
 A	  little	  difficulty 2 
 Moderate	  difficulty	    3 
 Extreme	  difficulty 4 
 Stopped doing this because of your eyesight 5 
 Stopped doing this for other reasons or not interested	  in	  doing	  this	   6 
   
13 Because of your eyesight, how much difficulty do you have visiting with people in 
their homes, at parties, or in restaurants? (Circle One) 
 Read categories as needed:  
 No	  difficulty	  at	  all 1 
 A	  little	  difficulty 2 
 Moderate	  difficulty	    3 
 Extreme	  difficulty 4 
 Stopped doing this because of your eyesight 5 
 Stopped doing this for other reasons or not interested	  in	  doing	  this	   6 
   
14 Because of your eyesight, how much difficulty do you have going out to see movies, 
plays, or sports events? (Circle One) 
 Read categories as needed:  
 No	  difficulty	  at	  all 1 
 A	  little	  difficulty 2 
 Moderate	  difficulty	    3 
 Extreme	  difficulty 4 
 Stopped doing this because of your eyesight 5 
 Stopped doing this for other reasons or not interested	  in	  doing	  this	   6 
   
15 Now, I’d like to ask about driving a car. Are you currently driving, at least once in a 
while? (Circle One) 
 Yes 1 Skip to part Q 15c 
 No 2  
    
15(a) If NO, ask: Have you ever driven a car or have you 
given up driving? (Circle One) 
  
 Never drove 1 Skip to part 3, Q17 
 Gave up 2  
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15(b) IF GAVE UP DRIVING: Was that mainly because of your eyesight, mainly for some 
other reason, or because of both your eyesight and other reasons? (Circle One) 
 Mainly eyesight 1 Skip to part 3, Q17 
 Mainly other reasons 2 Skip to part 3, Q17 
 Both eyesight and other reasons 3 Skip to part 3, Q17 
    
15(c) IF CURRENTLY DRIVING: How much difficulty do you have driving during the 
daytime in familiar places? Would you say you have: (Circle One) 
 No difficulty at all 1  
 A little difficulty 2  
 Moderate difficulty 3  
 Extreme difficulty 4  
    
16(a) How much difficulty do you have driving at night? Would you say you have: 
(Circle One) 
 Read categories as needed:  
 No	  difficulty	  at	  all 1 
 A	  little	  difficulty 2 
 Moderate	  difficulty	    3 
 Extreme	  difficulty 4 
 Stopped doing this because of your eyesight 5 
 Stopped doing this for other reasons or not interested	  in	  doing	  this	   6 
 
16(b) How much difficulty do you have driving in difficult conditions, such as in bad 
weather, during rush hour, on the freeway, or in city traffic? Would you say you have: 
(Circle One) 
 Read categories as needed:  
 No	  difficulty	  at	  all 1 
 A	  little	  difficulty 2 
 Moderate	  difficulty	    3 
 Extreme	  difficulty 4 
 Stopped doing this because of your eyesight 5 
 Stopped doing this for other reasons or not interested	  in	  doing	  this	   6 
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PART 3 – RESPONSES TO VISION PROBLEMS The	  next	  questions	  are	  about	  how	  things	  you	  do	  may	  be	  affected	  by	  your	  vision.	  For	  each	  one,	  I’d	  like	  you	  to	  tell	  me	  if	  this	  is	  true	  for	  you	  all,	  most,	  some,	  a	  little,	  or	  none	  of	  the	  time.	  (Circle	  one	  
on	  each	  line)	  
	  
Read categories: All of the 
time 
Most 
of the 
time 
Some 
of the 
time 
A little 
of the 
time 
None of 
the time 
17 Do you accomplish less than 
you would like because of your 
vision? 
1 2 3 4 5 
18 Are you limited in how long you 
work or do other activities 
because of your vision?  
1 2 3 4 5 
19 How much does pain or 
discomfort in or around your 
eyes, for example burning, 
itching or aching, keep you from 
doing what you would like to be 
doing? Would you say: 
1 2 3 4 5 
 
 
For each of the following statements, please tell me if it is definitely true, mostly true, mostly 
false, or definitely false for you or you are not sure. (Circle One On Each Line) 
 
Read categories: 
Definitely 
true 
Mostly 
true 
Not 
sure 
Mostly 
false 
Definitely 
false 
20 I	  stay	  home	  most	  of	  the	  time	  because	  of	  my	  eyesight. 1 2 3 4 5 
21 I	  feel	  frustrated	  a	  lot	  of	  the	  time	  because	  of	  my	  eyesight	    1 2 3 4 5 
22 I	  have	  much	  less	  control	  over	  what	  I	  do,	  because	  of	  my	  eyesight 1 2 3 4 5 
23 Because	  of	  my	  eyesight,	  I	  have	  to	  rely	  too	  much	  on	  what	  other	  people	  tell	  me 1 2 3 4 5 
24 I	  need	  a	  lot	  of	  help	  from	  others	  because	  of	  my	  eyesight 1 2 3 4 5 
25 I	  worry	  about	  doing	  things	  that	  will	  embarrass	  myself	  or	  others,	  because	  of	  my	  eyesight. 1 2 3 4 5 
 
That’s the end of the interview.  
Thank you very much for your time and your help. 
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Appendix 6: Appendix of Optional Additional Questions 
SUBSCALE: GENERAL HEALTH 
A1 How would you rate your overall health, on a scale where zero is as bad as death and 
10 is best possible health? (Circle One) 
 
 
0 1 2 3 4 5 6 7 8 9 10 
 
Worst Best 
  
SUBSCALE: GENERAL VISION 
A2 How would you rate your eyesight now (with glasses or contact lens on, if you wear 
them), on a scale of from 0 to 10, where zero means the worst possible eyesight, as 
bad or worse than being blind, and 10 means the best possible eyesight? (Circle One) 
 
 
0 1 2 3 4 5 6 7 8 9 10 
 
Worst Best 
  
SUBSCALE: NEAR VISION 
A3 Wearing glasses, how much difficulty do you have reading the small print in a 
telephone book, on a medicine bottle, or on legal forms? Would you say: (Circle One) 
 Read categories as needed:  
 No	  difficulty	  at	  all 1 
 A	  little	  difficulty 2 
 Moderate	  difficulty	    3 
 Extreme	  difficulty 4 
 Stopped doing this because of your eyesight 5 
 Stopped doing this for other reasons or not interested	  in	  doing	  this	   6 
  
A5 Because of your eyesight, how much difficulty do you have doing things like shaving, 
styling your hair, or putting on makeup? (Circle One) 
 Read categories as needed:  
 No	  difficulty	  at	  all 1 
 A	  little	  difficulty 2 
 Moderate	  difficulty	    3 
 Extreme	  difficulty 4 
 Stopped doing this because of your eyesight 5 
 Stopped doing this for other reasons or not interested	  in	  doing	  this	   6 
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SUBSCALE: DISTANCE VISION 
A6 Because of your eyesight, how much difficulty do you have recognising people you 
know from across a room? (Circle One) 
 Read categories as needed:  
 No	  difficulty	  at	  all 1 
 A	  little	  difficulty 2 
 Moderate	  difficulty	    3 
 Extreme	  difficulty 4 
 Stopped doing this because of your eyesight 5 
 Stopped doing this for other reasons or not interested	  in	  doing	  this	   6 
  
A7 Because of your eyesight, how much difficulty do you have taking part in active sports 
or other outdoor activities that you enjoy (like golf, bowling, jogging, or walking)? 
(Circle One) 
 Read categories as needed:  
 No	  difficulty	  at	  all 1 
 A	  little	  difficulty 2 
 Moderate	  difficulty	    3 
 Extreme	  difficulty 4 
 Stopped doing this because of your eyesight 5 
 Stopped doing this for other reasons or not interested	  in	  doing	  this	   6 
  
A8 Because of your eyesight, how much difficulty do you have seeing and enjoying 
programmes on TV? (Circle One) 
 Read categories as needed:  
 No	  difficulty	  at	  all 1 
 A	  little	  difficulty 2 
 Moderate	  difficulty	    3 
 Extreme	  difficulty 4 
 Stopped doing this because of your eyesight 5 
 Stopped doing this for other reasons or not interested	  in	  doing	  this	   6 
  
SUBSCALE: SOCIAL FUNCTION 
A9 Because of your eyesight, how much difficulty do you have entertaining friends and 
family in your home?	  (Circle	  One) 
 Read categories as needed:  
 No	  difficulty	  at	  all 1 
 A	  little	  difficulty 2 
 Moderate	  difficulty	    3 
 Extreme	  difficulty 4 
 Stopped doing this because of your eyesight 5 
 Stopped doing this for other reasons or not interested	  in	  doing	  this	   6 
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SUBSCALE: DRIVING 
A10 [This items, “driving in difficult conditions”, has been included as item 16a as 
part of the base set of 25 vision-targeted items.] 
 
 
SUBSCALE: ROLE LIMITATIONS 
A11 The next questions are about things you may do because of your vision.  
For each item, I’d like you to tell me if this is true for you all, most, some, a little, or 
none of the time.  
(Circle One On Each Line) 
 
Read categories as needed: All of the 
time 
Most 
of the 
time 
Some 
of the 
time 
A little 
of the 
time 
None of 
the time 
(a) Do you have more help from 
others because of your vision? 1 2 3 4 5 
(b) Are you limited in the kinds of 
things you can do because of 
your vision? 
1 2 3 4 5 
   
SUBSCALES: WELL-BEING / DISTRESS (#A12) and DEPENDENCY (#13) 
The next questions are about how you deal with your vision.  
For each statement, please tell me if it is definitely true, mostly true, mostly false, or definitely 
false for you or you don’t know. (Circle One On Each Line) 
 
Read categories: 
Definitely 
true 
Mostly 
true 
Not 
sure 
Mostly 
false 
Definitely 
false 
A12 I	  am	  often	  irritable	  because	  of	  my	  eyesight	   1 2 3 4 5 
A13 I don’t go out of my home alone, 
because of my eyesight  1 2 3 4 5 
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Appendix 7: Quality of Life After Vitrectomy Study 
 
QUALITY OF LIFE AFTER VITRECTOMY STUDY 
 
OPHTHALMOLOGY DEPARTMENT (GSH) 
 
NAME: ……………………………………..  FOLDER NO.: ……………………………………………. 
 
AGE: ………………………………………..  GENDER:   
 
TEL. NO.: ………………………………….  CELL NO.: ………………………………………………… 
 
PREVIOUS PRP:      AVERAGE REPORTED GLUCOSE IN g/DL: 
 
 
DATE OF INTERVIEW: …………………..  ………………………………………………………………. 
 
VISUAL ACUITY BEFORE SURGERY:  DM:   
 
OD    OS   DURATION OF DM: …………………………………… 
 
…………………………………………………  ………………………………………………………………. 
 
PH 
 
………………………………………………...  DATE OF SURGERY: ………………………………….. 
 
BCVA       ………………………………………………………………. 
 
…………………………………………………  ………………………………………………………………. 
 
…………………………………………………  DURATION OF SURGERY:  …………………………. 
 
VISUAL ACUITY AFTER SURGERY:  ………………………………………………………………. 
 
OD:       COMPILATION OF SURGERY 
       INTRAOPERATIVE: …………………………………… 
 
…………. …………. …………….  ………………………………………………………………. 
  
OS:       ………………………………………………………………. 
        
        
…………. ………….. …………….  POSTOPERATIVE: …………………………………….. 
 
CARDIAC DISEASE:     ……………………………………..………………………..
        
       ………………………………………………………………. 
               
RENAL DISEASE:    INDICATION OF SURGERY:…………………………  
 
       ………………………………………………………………. 
CVA:  
       ………………………………………………………………. 
 
OTHER DISEASES: ……………………….. DURATION OF COMPLICATION NEEDING 
VIRECTOMY: ……………………………………………. 
…………………………………………………..  
 ………………………………………………………………. 
……………………………………………………  
 ………………………………………………………………. 
BLOOD PRESSURE: ……………….mmHg  
 
  
MALE/FEMALE 
YES/NO 
TYPE I/TYPE II 
YES/NO 
YES/NO 
YES/NO 
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Appendix 8: Structured Eligibility Questions 
 
1 Why are we doing this study? 
2 Why were you asked to take part in this study? 
3 What will you be asked to do if you take part? 
4 How long will you be involved in the study? 
5 What kinds of risks are you going to face by taking part in the study? 
6 Are you worried about taking part in the study? 
7 What good things can happen if you take part in the study? 
8 What will happen if you decide you don’t want to be in the study any 
longer? 
9 Who should you contact if you have any questions? 
-  
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